Press Releases

In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulations of the Autorité des Marchés Financiers ( French Financial Markets Authority ) PARIS --(BUSINESS WIRE)--Jun. 9, 2022-- Regulatory News : Nanobiotix (Paris:NANO) (NASDAQ:NBTX): Market: Euronext

Data reported at the 2022 Annual Meeting of the American Society for Clinical Oncology NBTXR3 is being developed as a product candidate with potential to integrate across the standards of care in oncology, and these data from collaborator-sponsored phase 1b/2 studies add support for the

PARIS & CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 2, 2022-- Regulatory News : NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the ‘‘ Company ’’) , a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced

On-track to activate first US clinical trial sites in on-going pivotal phase III global registration study, NANORAY-312, in locally advanced head and neck squamous cell carcinoma (LA-HNSCC) in Q3 2022 Received preliminary feedback from FDA informing development of pivotal Phase III protocol for

PARIS & CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 17, 2022-- Regulatory News : NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the ‘‘ Company ’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced

PARIS & CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 11, 2022-- Regulatory News : NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the " Company "), a clinical-stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced that

PARIS & CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 4, 2022-- Regulatory News : NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the ‘‘ Company ’’) , a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced

PARIS & CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 2, 2022-- Regulatory News : NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the “ Company ”), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced the

Data presented at the 2022 Annual Meeting of the American Association of Cancer Research New data from an open-label preclinical study in mice evaluating the changes in immune-related genes induced by multiple combinations of NBTXR3, anti-PD-1, anti-LAG-3, and anti-TIGIT showed that groups that

PARIS & CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 8, 2022-- Regulatory News : NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the ‘‘ Company ’’) , a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer and other major